Prestige BioPharma Limited (950210.KS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. So-Yeon Park | Chairman & CEO | -- | -- | 1963 |
| Mr. Jinwoo Kim | CFO & Director | -- | -- | 1964 |
| Ms. Chung Shii Hii | Chief Technology Officer | -- | -- | 1979 |
| Dong -Jo Shin | Head of Finance | -- | -- | 1973 |
| Michael Ruppert | Head of Business Development | -- | -- | 1967 |
| Wei Hsiung Lee | Secretary | -- | -- | 1979 |
| Ms. Kay K.H. Lee | Clinical Development Manager | -- | -- | 1970 |
| Mr. Ghislain M.C Bonamy | General Manager of Licensing | -- | -- | 1979 |
Prestige BioPharma Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 54
Description
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available